Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842907 | 0.89 | — | — | |
| SCHEMBL11223116 | 0.85 | — | — | |
| SCHEMBL9366409 | 0.84 | LMNA (0.38) | LMNA | |
| SCHEMBL27261792 | 0.83 | — | — | |
| SCHEMBL8797146 | 0.81 | — | — | |
| SCHEMBL507408 | 0.80 | — | — | |
| SCHEMBL572712 | 0.78 | — | — | |
| SCHEMBL20589984 | 0.78 | — | — | |
| SCHEMBL3663645 | 0.75 | — | — | |
| SCHEMBL5540957 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174250-A1 | Composition And Method | RECKITT & COLMAN (OVERSEAS) LIMITED (GB) | 2015-06-25 | — | — | US | claimed |
| EP-2726591-A1 | COMPOSITION AND METHOD | Reckitt & Colman (Overseas) Limited (GB) | 2014-05-07 | — | — | EP | claimed |
| WO-2013005009-A1 | COMPOSITION AND METHOD | RECKITT & COLMAN (OVERSEAS) LIMITED (GB) | 2013-01-10 | — | — | WO | claimed |
| EP-2200570-A2 | MICROCAPSULES AND METHODS | University Of Leeds (GB) | 2010-06-30 | — | — | EP | claimed |
| WO-2009037482-A2 | MICROCAPSULES AND METHODS | UNIVERSITY OF LEEDS (GB) | 2009-03-26 | — | — | WO | claimed |
| US-20240282989-A1 | PHENOTHIAZINE DERIVATIVES AND REDOX-FLOW BATTERIES | UNIV KENTUCKY RES FOUND (US) | 2024-08-22 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3810199-A1 | METHOD | Oslo Universitetssykehus HF (NO) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019243757-A1 | METHOD | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2019-12-26 | — | — | WO | disclosed |
| CN-105652349-A | Core-shell nanoparticles | 帝斯曼知识产权资产管理有限公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2015160772-A1 | TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5 | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-22 | — | — | WO | disclosed |
| US-20150174250-A1 | Composition And Method | RECKITT & COLMAN (OVERSEAS) LIMITED (GB) | 2015-06-25 | — | — | US | disclosed |
| WO-2000001687-A9 | BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE & CO (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064053-A1 | β3-ADRENERGIC RECEPTOR AGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997033882-A9 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | — | 1998-02-26 | — | — | WO | disclosed |
| US-4564690-A | URANYL ION CAPTURING AGENT | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1986-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240282989-A1 | PHENOTHIAZINE DERIVATIVES AND REDOX-FLOW BATTERIES | GPX4, NDUFV2, NDUFV1 | LMNA 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.